Vyxeos

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
JP
  • High-risk acute myeloid leukaemia (Vyxeos combination for IV infusion; Nippon Shinyaku)
Product first approved 2024nippon-shinyaku.co.jp
CA
  • Adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes
Product first approved 2021newswire.ca
EU
  • Adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (marketed as Vyxeos liposomal; holder Jazz Pharmaceuticals Ireland Limited).
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Acute Myeloid Leukemia
Phase 2/3 (2)
Acute Myeloid Leukemia
NCT04217278 · University of Birmingham
2020-01-27 – 2026-05 · Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome
What this study did
NCT02272478 · Cardiff University
2014-10-30 – 2022-02 · Acute Myeloid Leukaemia, Myelodysplastic Syndrome
What this study did
Phase 2 (33)
Acute Myeloid Leukemia
NCT05554419 · National Cancer Institute (NCI)
2027-01-04 – 2030-12-31 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
What this study did
NCT05260528 · Centre Hospitalier Universitaire de Nice
2023-05-03 – 2030-02-02 · Acute Myeloid Leukemia
What this study did
NCT05829434 · Uwe Platzbecker
2024-03-31 – 2029-08-30 · Acute Myeloid Leukemia, Myelodysplastic Neoplasm
What this study did
NCT05564390 · National Cancer Institute (NCI)
2024-06-18 – 2029-05-15 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
What this study did
NCT05599360 · Shaare Zedek Medical Center
2022-08-07 – 2028-09-07 · Leukemia, Myeloid, Acute
What this study did
NCT04493164 · M.D. Anderson Cancer Center
2020-12-30 – 2028-06-01 · Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT04801797 · Massachusetts General Hospital
2021-05-20 – 2028-01-01 · Acute Myeloid Leukemia
What this study did
NCT04231851 · University of California, Irvine
2020-02-19 – 2027-06-30 · Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
What this study did
NCT05554406 · National Cancer Institute (NCI)
2024-09-25 – 2027-03-31 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
What this study did
NCT05628623 · Eastern Cooperative Oncology Group
2024-10-23 – 2027-02 · Leukemia, Myeloid, Acute
What this study did
NCT04668885 · Case Comprehensive Cancer Center
2021-01-14 – 2027-01-19 · Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, Myelodysplastic Syndromes
What this study did
NCT03629171 · M.D. Anderson Cancer Center
2018-10-29 – 2026-12-31 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT04061239 · GWT-TUD GmbH
2019-08-19 – 2026-08-07 · MDS, AML
What this study did
NCT03672539 · M.D. Anderson Cancer Center
2018-11-07 – 2026-07-17 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT04195945 · Fred Hutchinson Cancer Center
2020-05-27 – 2026-05-20 · Acute Myeloid Leukemia, Myeloid Neoplasm
What this study did
NCT04269213 · Roswell Park Cancer Institute
2021-07-29 – 2026-04-16 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
What this study did
NCT03226418 · University of Nebraska
2017-07-07 – 2024-10-01 · Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
What this study did
NCT03825796 · Jonsson Comprehensive Cancer Center
2019-04-12 – 2024-09-01 · Recurrent Acute Myeloid Leukemia
What this study did
NCT04992949 · French Innovative Leukemia Organisation
2022-03-23 – 2023-12-04 · Acute Myeloid Leukemia, Myeloproliferative Syndrome
What this study did
NCT04526288 · Fred Hutchinson Cancer Center
2021-08-09 – 2023-08-27 · Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm
What this study did
NCT04425655 · University of California, San Diego
2020-08-05 – 2022-07-01 · Acute Myeloid Leukemia, Adult, AML, AML, Adult
What this study did
NCT04230239 · PETHEMA Foundation
2019-12-26 – 2021-08-11 · Newly Diagnosed Secondary or High Risk AML
What this study did
NCT04209725 · SCRI Development Innovations, LLC
2020-06-03 – 2021-04-20 · Leukemia, Myeloid, Acute
What this study did
NCT03335267 · Weill Medical College of Cornell University
2017-10-19 – 2020-05-29 · Leukemia, Myeloid, Acute
What this study did
NCT02286726 · M.D. Anderson Cancer Center
2015-05-04 – 2020-01-22 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
What this study did
NCT02019069 · Rondeep Brar
2014-02-03 – 2017-12-18 · Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
What this study did
NCT02269579 · Jazz Pharmaceuticals
2015-04 – 2017-06 · Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
What this study did
NCT02238925 · Jazz Pharmaceuticals
2014-07 – 2016-01 · Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
What this study did
NCT00822094 · Jazz Pharmaceuticals
2009-02 – 2012-01 · Acute Myeloid Leukemia
What this study did
NCT00788892 · Jazz Pharmaceuticals
2008-10 – 2011-12 · Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT05656248 · St. Jude Children's Research Hospital
2023-01-17 – 2028-08 · Myeloid Neoplasm
What this study did
NCT03575325 · H. Lee Moffitt Cancer Center and Research Institute
2018-10-11 – 2023-09-14 · Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
What this study did
NCT03957876 · Case Comprehensive Cancer Center
2019-07-25 – 2022-12-20 · Myelodysplastic Syndrome (MDS)
What this study did
Phase 1/2 (11)
Acute Myeloid Leukemia
NCT04982354 · Guenther Koehne
2022-07-05 – 2032-08-01 · Acute Myeloid Leukemia
What this study did
NCT07008638 · Masonic Cancer Center, University of Minnesota
2025-07-07 – 2028-01-27 · Acute Myeloid Leukemia, TP53
What this study did
NCT04128748 · M.D. Anderson Cancer Center
2020-05-27 – 2027-12-31 · Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT04049539 · Ohio State University Comprehensive Cancer Center
2021-01-29 – 2027-05-31 · Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia
What this study did
NCT04990102 · Georgetown University
2023-05-22 – 2026-12 · Acute Myeloid Leukemia (AML) in Remission
What this study did
NCT03878199 · Ohio State University Comprehensive Cancer Center
2019-02-20 – 2025-02-27 · Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
What this study did
NCT03844997 · Sudipto Mukherjee, MD, PhD, MPH
2019-06-06 – 2024-01-24 · Acute Myeloid Leukemia, AML
What this study did
NCT05320380 · Children's Oncology Group
2023-08-01 – 2023-09-01 · Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory T Acute Lymphoblastic Leukemia
What this study did
NCT02642965 · Children's Oncology Group
2016-05-02 – 2023-06-30 · Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT04273802 · Groupe Francophone des Myelodysplasies
2020-04-29 – 2022-07-06 · Myelodysplastic Syndromes
What this study did
NCT04109690 · Yale University
2019-12-30 – 2021-07-27 · MDS
What this study did
Phase 1 (17)
Acute Myeloid Leukemia
NCT05627232 · Thomas Jefferson University
2023-08-28 – 2029-01 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT07156435 · Princess Maxima Center for Pediatric Oncology
2020-11-06 – 2028-12-31 · Relapsed Pediatric AML, Refractory Pediatric AML
What this study did
NCT05558124 · H. Lee Moffitt Cancer Center and Research Institute
2023-02-16 – 2027-04 · Acute Myeloid Leukemia
What this study did
NCT05024552 · H. Lee Moffitt Cancer Center and Research Institute
2022-02-25 – 2027-03 · Acute Myeloid Leukemia With FLT3/ITD Mutation
What this study did
NCT04915612 · M.D. Anderson Cancer Center
2021-05-21 – 2025-01-30 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
What this study did
NCT03904251 · Jonsson Comprehensive Cancer Center
2019-07-18 – 2023-10-25 · Acute Myelogenous Leukemia
What this study did
NCT04075747 · Jazz Pharmaceuticals
2019-12-02 – 2023-09-12 · Acute Myeloid Leukemia
What this study did
NCT04038437 · Jazz Pharmaceuticals
2019-10-15 – 2022-09-24 · Acute Myeloid Leukemia
What this study did
NCT03878927 · Weill Medical College of Cornell University
2019-08-23 – 2022-09-01 · Acute Myeloid Leukemia
What this study did
NCT03393611 · Weill Medical College of Cornell University
2012-11-30 – 2021-11-18 · Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Relapsed Adult Acute Myeloid, Myelodysplastic Syndromes, Previously Treated
What this study did
NCT03555955 · Jazz Pharmaceuticals
2018-11-20 – 2021-05-26 · Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
What this study did
NCT01943682 · Children's Hospital Medical Center, Cincinnati
2013-09 – 2019-04 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Diffuse Large Cell Lymphoma, Gray Zone Lymphoma, Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Hodgkin Lymphoma
What this study did
NCT00875693 · Weill Medical College of Cornell University
2009-06-02 – 2017-12-27 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
Other / comorbidity
NCT03826992 · Children's Hospital Medical Center, Cincinnati
2018-12-27 – 2028-01 · Leukemia
What this study did
NCT03896269 · M.D. Anderson Cancer Center
2019-05-14 – 2027-12-31 · Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
What this study did
NCT03572764 · Washington University School of Medicine
2018-12-14 – 2027-03-25 · Myelodysplastic Syndromes
What this study did
NCT00389428 · Jazz Pharmaceuticals
2006-09 – 2009-12 · Hematologic Neoplasms
What this study did
Phase 4 (1)
Acute Myeloid Leukemia
NCT03988205 · Medical College of Wisconsin
2019-08-28 – 2022-04-01 · Leukemia, Myeloid, Acute
What this study did
Early phase / not applicable (2)
Acute Myeloid Leukemia
NCT05801835 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2023-08-25 – 2025-12 · Acute Myeloid Leukemia
What this study did
NCT01804101 · Fred Hutchinson Cancer Center
2013-05-07 – 2017-01-10 · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Early phase / not applicable (1)
Acute Myeloid Leukemia
NCT04920500 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2020-09-04 – 2021-06-30 · Acute Myeloid Leukemia
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Acute Myeloid Leukemia
NCT04802161 · National Cancer Institute (NCI)
2022-08-24 – 2027-04-25 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
What this study did

Competitive landscape

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vyxeos: this drugApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race

Large race: only the 60 furthest-along competitors are listed; 70 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vyxeos to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT04990102 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT07156435 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT03629171 · CT.gov ↗
What to watch
2027 (10)
January 2027 (2)
Phase 1LeukemiaRecruiting
Est. primary completion 2027-01 · NCT03826992 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01-01 · NCT04801797 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-02-15 · NCT05024552 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-31 · NCT05554406 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-04 · NCT05558124 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-31 · NCT04049539 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-06 · NCT03897127 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-30 · NCT07008638 · CT.gov ↗
What to watch
Phase 1Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells …Recruiting
Est. primary completion 2027-12-31 · NCT03896269 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-31 · NCT04128748 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01 · NCT05627232 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06-01 · NCT04493164 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-08-02 · NCT05260528 · CT.gov ↗
What to watch
2029 (2)
May 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT05564390 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06-30 · NCT04293562 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-12-31 · NCT05554419 · CT.gov ↗
What to watch

See the full readout calendar ↗